18 results about "Passive Immunizations" patented technology

The present invention pertains to pharmaceutical compositions comprising protein oligomers for passive immunization and therapy. Specifically, the present invention relates to a pharmaceutical composition comprising a protein oligomer comprising at least a first and a second monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first receptor binding domain (RBD), an immunoglobulin Fc (Ig Fc), and at least one second receptor binding domain (RBD), wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13.

The present application relates to a 48E-scFv-Fc recombinant antibody with broad-spectrum activity against waterfowl parvovirus, a construction method and application thereof, the 48E-scFv-Fc recombinant antibody comprising a light chain variable region and a heavy chain variable region, and the amino acid sequences of the light chain variable region and the heavy chain variable region are shown as SEQ ID NO: 1-2. The present application provides a coding gene for encoding the recombinant antibody, which comprises a DNA sequence shown as SEQ ID NO: 3-4. The present application also provides a corresponding recombinant plasmid and a preparation method of the 48E-scFv-Fc recombinant antibody, etc. The 48E-scFv-Fc recombinant antibody can simultaneously recognize four waterfowl parvoviruses of cGPV, MDPV, MDGPV and SBDSV, and has a good application prospect in immunological detection of waterfowl parvovirus infection, antigen epitope research, passive immunization preparation development and broad-spectrum antibody drug research, etc.

The invention relates to the field of veterinary biological products, in particular to a porcine epidemic diarrhea virus attenuated strain and a vaccine and application thereof. The porcine epidemic diarrhea virus attenuated strain provided by the invention is obtained through in-vitro separation culture and continuous five rounds of plaque purification and screening technology, and has stable culture characteristics. Meanwhile, the virulence of the strain on newborn piglets and weaned piglets is remarkably reduced, and the virulence does not have the phenomenon of reversion after continuous passage for five times in a pig body. The strain has good immunogenicity, and mucosal immunity and systemic immune response of an organism can be activated at the same time by adopting an oral immunization mode. A neutralizing antibody of 1: 8-1: 16 can be detected in oral fluid and serum after the piglets are immunized for 14 days, and a large amount of sIgA is generated in milk after the pregnant sows are immunized, so that the piglets obtain effective passive immune protection.

The invention provides a GP4 protein antigen epitope peptide of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) and a monoclonal antibody, and provides a hybridoma cell strain for generating the monoclonal antibody, and the preservation number of the hybridoma cell strain is CCTCC (China Center for Type Culture Collection) NO.C2025259. The monoclonal antibody provided by the invention does not react with various other swine viruses such as PCV2, PEDV, GETV and the like, and has good specificity; the polypeptide has good affinity with PRRSV structural protein GP4 at the molecular level and the cellular level, and epitope information is clear. The antibody can significantly inhibit the infection efficiency of a PRRSV-2 JXwn06 strain in MARC-145 cells and alveolar macrophages, has a good PRRSV in-vitro neutralization effect, can be used for developing a high-specificity PRRSV-2 GP4 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The invention discloses a hybridoma cell strain capable of secreting a monoclonal antibody with bovine coronavirus neutralizing activity and application of the hybridoma cell strain, and belongs to the technical field of antibody drugs. The preservation number of the hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO: C2025147. The hybridoma cell strain can be used for preparing a monoclonal antibody with bovine coronavirus neutralizing activity, and the monoclonal antibody shows excellent neutralizing titer on bovine coronavirus and is subjected to cross-neutralization reaction with related sheep coronavirus (cpCoV). The monoclonal antibody obtained by the invention not only can be used for developing a high-sensitivity specific diagnostic reagent aiming at the BCoV, but also provides a new core biological material for developing a passive immunotherapy preparation with a potential broad-spectrum protection effect; the method has important application value in the aspects of coping with virus variation and improving the overall prevention and control capability of the coronavirus of the ruminant.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The present disclosure provides an anti-tetanus toxin neutralizing antibody as a new generation of tetanus passive immunization preparation. The antibody can be fully human, which can specifically bind to full-length tetanus toxin and its AB fragment, has high affinity, high specificity, small toxic side effects, avoids the problems of large adverse reactions and short half-life of animal-derived monoclonal antibodies, and is prepared in large quantities by mammalian cells, and has clear and stable components.

The application discloses a porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus triple mRNA vaccine and a preparation method thereof, the triple mRNA vaccine is prepared by mixing mRNA for expressing S, M and N proteins of porcine epidemic diarrhea virus, mRNA for expressing S, M and N proteins of porcine delta coronavirus and mRNA for expressing VP4 and VP7 proteins of porcine rotavirus with liposomes, and is applied to simultaneous prevention and immunization of porcine epidemic diarrhea, porcine delta coronavirus and porcine rotavirus. After sows are immunized by the triple mRNA vaccine, the sows can effectively activate the sows to generate specific antibodies and neutralizing antibodies, and piglets obtain passive immunoprotection by sucking the milk of the sows. Piglet challenge protection tests show that the protection rates of the triple mRNA vaccine on the three viruses are all 100% (5 / 5). The application simplifies the inoculation procedure, reduces the epidemic prevention cost, can achieve the effect of preventing and treating three kinds of porcine viral diarrhea by one injection, and provides a simple, convenient and efficient new triple vaccine for domestic farms.

The invention provides a monoclonal antibody for detecting pig source CD163 protein and a corresponding antigen epitope peptide. Wherein the hybridoma cell strain used for preparing the monoclonal antibody is CCTCC (China Center For Type Culture Collection) NO: C2025258. The monoclonal antibody provided by the invention is good in specificity, has good affinity with pCD163, and is clear in epitope information. The antibody can significantly inhibit the infection efficiency of PRRSV pedigree strains in alveolar macrophages, has a good PRRSV in-vitro blocking effect, can be used for developing a high-specificity pCD163 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

Provided are an anti-tetanus toxin neutralizing antibody and the use thereof as a new-generation tetanus passive immunological preparation. The antibody can be a fully human antibody, has the characteristics of a high affinity, a high specificity, and few toxic side effects, and avoids the problems of strong adverse reactions and a short half-life of animal-derived monoclonal antibodies. Moreover, the antibody can be prepared on a large scale using mammalian cells, and has a clear and stable composition. On the basis of clinical requirements, the exploration and development of an anti-tetanus toxin neutralizing fully-human antibody as a new-generation tetanus passive immunological preparation has great medical value.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and / or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).

The present invention pertains to protein oligomers for immunization against respiratory viruses and treatment of diseases caused by respiratory viruses.

Antibodies, compositions and methods are provided for treatment and prophylaxis of influenza virus. Antibodies and antigen-binding fragments are provided that bind near the HA0 maturation cleavage site consensus sequence of influenza hemagglutinin A. Antibody compositions, combinations and methods for effective passive immunization across influenza A and B strains are also provided.

The invention provides a mucosal immune vaccine based on a porcine parainfluenza virus PIV5 carrier and application of the mucosal immune vaccine in immunization of sows and piglets, and belongs to the technical field of animal vaccines. According to the invention, on the basis of a porcine PIV5 reverse genetic operating system, the S gene of the porcine delta coronavirus (PDCoV) is inserted into a P-M gene spacer region of the PIV5 by using a P-M exogenous gene expression cassette of the PIV5, and a recombinant vaccine capable of expressing the PDCoV S is successfully rescued, and is named as JS17-PDCoV-S. A high-titer neutralizing antibody can be generated after the piglets are immunized by oral administration; after a sow orally takes the JS17-PDCoV-S vaccine, high-level serum IgG and mucous membrane sIgA antibodies can be generated. Meanwhile, the piglets are passively immunized by sucking milk, whole body and mucous membrane immune protection aiming at specific pathogens is provided for the piglets, early infection is effectively prevented, and the problem that IgG is easily degraded by digestive tracts of the piglets is solved.

Methods of producing feed pellets containing antiviral proteins for protecting aquatic animals against viruses by passive immunization are disclosed. The pellets have an effective amount of an active antiviral protein incorporated into basal feed stock along with stabilizing. gelling and bioavailability enhancing agents. The antiviral proteins are IgY antibodies contained in hyperimmune egg powder obtained from eggs produced by avian species exposed to antigens associated with viral infections. To protect shrimp against white spot syndrome virus (WSSV) the antigen consists of a protein made from the effective parts of the VP28 and VP19 sequences of the WSSV. In one embodiment, the stabilizing agent is sodium alginate, the gelling agent is carboxy methyl cellulose and the bioavailability enhancing agent is piperine. In one embodiment the active protein and associated supplements are incorporated throughout the feed pellet. while in another embodiment they are sprayed onto the surface of the feed pellet.

A system and method for passively delivering inactivated pathogens to a population of animals or birds. The method comprises: isolating a pathogen from an infected animal / bird; culturing the isolated pathogen; inactivating the isolated pathogen with UVC; infusing an object with the inactivated pathogen; and introducing the inactivated pathogen infused object into an area containing one or more animals / birds.